Key facts
- PicturaBio’s last known valuation is $10.3M (Oct 2023).
- It has raised $6.3M; the latest was Early Stage VC in Jul 2025.
- Notable investors include Innovate UK, Impact Assets, University of Oxford, IQ Capital Partners, Sunway iLabs — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for PicturaBio
- ·The full record, as it builds
Funding rounds
No funding rounds for PicturaBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PicturaBio
Developer of a pathogen detection platform designed to provide accurate, digital imaging-based identification of infectious diseases. The company's platform uses single-molecule fluorescent microscopy and image analysis with machine learning to detect an array of pathogens, enabling doctors to quickly identify unknown infections through respiratory viruses.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2021
- Employees
- 15
- Website
- pictura.bio/
- Ownership
- Privately Held (backing)
PicturaBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PicturaBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PicturaBio in its N-PORT filings yet. We sweep new filings monthly.